PreDiabetes, Renal Failure, Type2diabetes
Conditions
Brief summary
More than 50% of patients with type 2 diabetes develop micro- and/or macrovascular complications during the course of the disease. Additionally, many patients at risk for diabetes develop metabolically driven complications including kidney and heart disease. Thus, it is of utmost importance to improve prevention of T2D and with this complications. Remission of prediabetes, i.e. normalization of hyperglycemia by means of lifestyle intervention is one of the most effective ways to prevent the development of T2D and complications. Novel sub-phenotyping analysis identified clusters of risk for diabetes associated with different complications, opening opportunities to new therapeutic approaches, despite and in addition to lifestyle changes. So far, pharmacological therapy is not indicated for patients with prediabetes. Remission of hyperglycemia associated with prediabetes during lifestyle interventions not only prevents T2D but is also linked with reduced albuminuria and lower microvascular and kidney complications. Thus, reaching normoglycemia (i.e. prediabetes remission) is important for reducing the risk of (pre-)diabetes-associated complications including micro- and even macrovascular disease. In patients with T2D, recent data show that dapagliflozin can improve diabetes remission, and thus, likely complications. However, to date no data have assessed whether or not this is also true in patients with hyperglycemia related to prediabetes which, as outlined above, already causes different complications. Subphenotyping of patients with newly onset diabetes suggests that for some individuals, it would be too late to start interventions against dagainst complications at the time of diagnosis of type 2 diabetes. Therefore, individuals at elevated risk to develop T2D and complications should receive preventive measures well before the diagnosis of T2D. This study will provide evidence whether such an early intervention contributes to the remission of hyperglycemia related to prediabetes to protect from associated complications such as renal disease. The studied population will comprise individuals who have hyperglycemia in the range of prediabetes and are thus prone to not only develop T2D, but also early nephropathy but in clinical practice do not receive medical treatment due to the early stage of the disease. These subjects will receive Dapagliflozin 10 mg or Placebo for 6 months. The placebo treatment arm reflects current practice. In order guarantee a benefit the patients in the placebo arm will receive a lifestyle intervention.
Interventions
Dapagliflozin 10 mg once daily for 6 months. Route of administration: oral.
DRUGPlacebo matching Dapaglifolzin
Placebo matching Dapaglifolzin once daily for 6 months. Route of administration: oral.
BEHAVIORALLifestyle Intervention
Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
Sponsors
University Hospital Tuebingen
German Federal Ministry of Education and Research
German Center for Diabetes Research
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Randomization will be performed stratified by prediabetes cluster.
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male, female or intersexualpatients aged between 35 and 75 years (including) 2. Prediabetes (defined by one of the following: FG ≥ 100 mg/dL or 2h OGTT glucose ≥ 140 mg/dL) 3. BMI ≥20 kg/m2 4. TSH within normal range 5. Ability to understand and follow study-related instructions 6. Negative pregnancy test for premenopausal women (blood) 7. Patients who are receiving thyroid replacement therapy must be on a stable treatment regimen for at least 3 months prior to the screening visit (V-1) 8. Patients who are receiving antihypertensive medication such as mineralocorticoid receptor antagonists must be on a stable treatment regimen for at least 6 weeks prior to the screening visit (V-1) 9. Patients who are treated antihypertensive medication such as ACE inhibitors and AT1receptor antagonists, thiazides as well as loop diuretics must be on stable treatment for at least 2 weeks 10. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures. 11. Patients will not be included in the study if, in the opinion of the investigator participation will lead to an unacceptable risk to the subjects' safety or well-being
Exclusion criteria
1. Manifest diabetes mellitus 2. eGFR (as calculated by the CKD-EPI equation) \< 60 ml/min/1.73 m2 3. all glucose altering medications (including current therapy with dapagliflozin or empagliflozin or any other SGLT2-Inhibitor) 4. Symptomatic chronic congestive heart disease 5. New diuretic or antihypertensive medication or dosing changes within the last 2 weeks, for aldosterone antagonists within the last 6 weeks 6. known or suspected orthostatic proteinuria 7. any acute severe or chronic severe illness, including the following: malignant disease ongoing or \< 5 years ago, unstable cardiovascular disease or procedure within 3 months prior to enrolment or expected to require coronary revascularisation procedure 8. history of or current therapy for congestive heart failure (NYHA III and IV), pacemaker or aortic stenosis \> II° 9. acute pancreatic disease (i.e. elevated lipase 3x ULN) 10. rapidly progressing renal disease or anuria 11. known HIV infection or positive HIV test at screening 12. history of or planned organ transplantation 13. history or presence of inflammatory bowel disease or other severe gastrointestinal diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis 14. relevant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase and/or aspartate aminotransferase \> 3 x upper limit of normal and/or total bilirubin (TB) \> 2 mg/dL (\> 34.2 μmol/L) (patients with TB \> 2 mg/dL \[\> 34.2 μmol/L\] and documented Gilbert's syndrome will be allowed to participate). 15. treatment with glucocorticoids 16. antibiotic treatment within the last 4 weeks 17. History of ketoacidosis 18. history of repeated urogenital infection 19. hemoglobinopathies, haemolytic anaemia, or chronic anaemia (haemoglobin concentration \<12.0 g/dL) 20. presence of psychiatric disorder or new intake of antidepressant or antipsychotic agents(start within last 3 months) 21. Positive Screening for a severe depression (BDI ≥29) 22. history of hypersensitivity to the study drug or its ingredients 23. more than 5% weight loss in the last 3 months 24. Pregnant or breastfeeding women 25. Subject (male, female or intersexual) is not willing to use highly effective contraceptive methods during treatment and for 14 days (male or female) after the end of treatment (highly effective methods are defined as: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success. 26. Current participation in other interventional clinical trials or treatment with other IMPs within five times the half-life of the drug 27. Previous therapy with dapagliflozin or other drugs that can potentially lead to overlapping toxicities within five times the half-life of the drug 28. Patients who do not want to be informed about accidental findings 29. Any other clinical condition that would jeopardize subjects' safety or well-being while participating in this clinical trial 30. Patients will not be included in the study if, in the opinion of the investigator, participation leads to an unacceptable risk to their safety and well-being
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of remission of hyperglycemia | 6 months | Frequency of individuals with prediabetes remission (normalization of fasting and 2h glucose concentrations) with dapagliflozin in comparison to treatment with placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of urinary albumine-creatinine ratio. | 1 month throuhg 6 months | To test differences between the two treatment arms for reduction of urinary albumine-creatinine ratio. |
| Change in estimated glomerular filtration rate (eGFR) | 7 months | To test differences between the two treatment arms for reduction in estimated glomerular filtration rate (eGFR). |
| Slopes over time of estimated glomerular filtration rate (eGFR). | baseline to 4 weeks, baseline to 7 months, 3 months to 7 months, baseline to 12 months | To test differences between the two treatment arms for slopes over time of estimated glomerular filtration rate (eGFR). |
| Numbers of patients showing resolution of chronic kidney disease (CKD) | 3 months through 12 months | To test differences between the two treatment arms for resolution of chronic kidney disease (CKD) for at least 3 months continuously: Urine Albumin Creatinin Ratio (uACR) \< 30mg/g |
| Prediabetes remission maintenance | 12 months | Effects of 6 months treatment with dapagliflozin 10 mg and lifestyle counseling compared to placebo and lifestyle intervention on remission of prediabetes as defined in the oGTT a fasting glucose \<100 mg/dl and 2 h glucose \<140 mg/dl at follow up |
Countries
Germany
Contacts
CONTACTAndreas Birkenfeld, Prof. Dr.
CONTACTAndreas Fritsche, Prof. Dr.
Outcome results
None listed